Qiming Venture Partners Weekly | Portfolio Company Updates and Funding News Vol. 21, 2025
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Editor's Note: The "Qiming Weekly" column publishes regularly every week, rounding up funding news and development updates from Qiming Venture Partners' portfolio companies.
In the wave of technology and innovation, every step entrepreneurs take deserves to be documented. Qiming Venture Partners will continue to accelerate and empower founders, and we invite you to follow along as we track the milestone moments of our portfolio companies.
IPO
Global Smart Imaging Leader Insta360 Successfully Lists on STAR Market
On June 11, Beijing time, Qiming Venture Partners portfolio company and global leading smart imaging solutions provider Insta360 successfully listed on the STAR Market. Insta360 (688775.SH) priced its IPO at 47.27 yuan per share, opened at 182.00 yuan per share — a 285% gain — and reached a market cap of 72.982 billion yuan.
As an early investor in Insta360, Qiming Venture Partners accompanied the company through a ten-year journey. As early as 2015, Qiming Venture Partners led Insta360's Series B round, and continued to support the company's development in its Series C round.
Founded in 2015, Insta360 has remained focused on the R&D, production, and sales of smart imaging devices including panoramic cameras and action cameras. Its main product categories include consumer-grade smart imaging devices, professional-grade smart imaging devices, accessories, and other products. With panoramic technology as its foundation, the company has developed a core technology system spanning panoramic technology, stabilization technology, AI image processing technology, and computational photography technology — with underlying key technologies that are original and advanced.
Gary Ye, Partner at Qiming Venture Partners, said: "When Qiming Venture Partners decided to invest in JK and Insta360 in early 2015, we focused on two key dimensions. On one hand, JK's exceptional original product thinking and technical capabilities; on the other hand, our firm belief that the 360-degree smart camera space held enormous market potential. Today Insta360 has grown into a global leader in its niche, and we believe the company has vast room for imagination at the intersection of imaging and AI technology — particularly in 3D imaging, spatial computing, and intelligent AI image generation. Ten years ago, Qiming Venture Partners firmly believed that hard tech was the true driver of industrial transformation, while also placing deep trust in young entrepreneurs. Today, Qiming Venture Partners continues to actively focus on and deploy in the hard tech space, with particular emphasis on entrepreneurial teams with original spirit, technical depth, and global vision. We also pay special attention to areas that haven't yet reached broad consensus but have the potential to achieve disruptive breakthroughs."
Corporate ESG
Bondent and Dr. Clear Aligner Support Launch of Two Public Welfare Projects: "Silver Smile Plan" and "Seedling Dental Care Project"
At the Shandong Provincial Private Dental Medical Institutions Association Pediatric Dentistry Committee preparatory meeting and the launch ceremony for Jiaxiang County's two public welfare projects — the "Silver Smile Plan" and "Seedling Dental Care Project" — two Qiming Venture Partners portfolio companies, Bondent and Dr. Clear Aligner, appeared as core supporting enterprises and signed strategic cooperation agreements with Chongwen Dental Medical Group.
This signing marks Bondent and Dr. Clear Aligner's commitment to leveraging their global leading advantages in intelligent dental equipment and digital solutions to build a solid and reliable technical foundation and hardware support platform for the entire public welfare initiative, laying the groundwork for efficient project operations.
Funding News
Insilico Medicine Raises Approximately $123 Million in Series E Round
Qiming Venture Partners portfolio company Insilico Medicine announced it has recently completed its Series E financing. With support from investors, this round raised approximately $123 million, exceeding its target and further demonstrating the value of the company's unique dual-engine business model — combining a generative AI platform with deep proprietary drug discovery capabilities to achieve continuous reinforcement learning-driven scientific innovation.
The proceeds will be used to drive breakthroughs in AI platform upgrades and drug pipeline innovation. Specifically, a portion of the funds will be allocated to refining Insilico Medicine's self-developed AI models and algorithms, while upgrading and expanding its cutting-edge automated intelligent laboratory to further streamline the drug R&D process. At the same time, Insilico Medicine will continue clinical exploration of its self-developed and partnered drug pipelines, accelerating breakthrough innovation in biomedical R&D.
Major Partnerships
01/
WeRide, Dubai's RTA, and Uber Sign Tripartite Agreement
Recently, Qiming Venture Partners portfolio company WeRide (NASDAQ:WRD) signed a cooperation agreement with Dubai's Roads and Transport Authority (RTA) and Uber Technologies, Inc., the world's largest mobility and delivery technology company.
The three parties will collaborate to deploy commercial Robotaxi services in Dubai. The service will launch on the Uber platform within this year, with the first batch of Robotaxis operating commercially with safety drivers while conducting driverless testing, achieving fully driverless commercial operations in Q1 2026. WeRide and Uber have already commenced Robotaxi road testing in Dubai under RTA guidance.
Li Xuan, WeRide's CFO and Head of International, said: "We are accelerating our international expansion, with the Middle East as a strategic priority. Last month, we jointly announced with Uber an expanded partnership to deploy Robotaxis in 15 additional cities over the next five years, including Middle Eastern cities. Now, we have formally signed a cooperation agreement with Uber and Dubai's RTA to advance autonomous vehicle deployment in Dubai. This partnership aligns closely with the Dubai government's ambitious vision of 'achieving 25% automated mobility by 2030,' and we are proud to contribute to this goal with our strong technical capabilities and global deployment experience."
02/
Foxconn and UBTECH Host Embodied Intelligent Robot Skills Training Program
Recently, the "Smart Manufacturing Pioneer — UBTECH × Foxconn Embodied Intelligent Robot Skills Training Program" was successfully held at Foxconn. This training program is a key initiative between Foxconn and Qiming Venture Partners portfolio company UBTECH (09880.HK) based on their comprehensive long-term strategic partnership, aimed at advancing the deep application of robots in smart manufacturing and cultivating industry talent.
This emerging career talent training program was designed and taught by UBTECH's industry-education integration team. The training focused on "humanoid robot industry development" and "service robot application technology," with curriculum divided into theoretical and practical components. Theoretical courses covered humanoid robot industry development, commercialization progress, and typical industrial application cases. Practical training included hands-on work in service robot assembly, debugging, deployment, and operations maintenance.
03/
HyperStrong Signs Series of Cooperation Agreements at SNEC
At the 18th (2025) International Solar Photovoltaic and Smart Energy (Shanghai) Conference and Exhibition, Qiming Venture Partners portfolio company HyperStrong (688411.SH) signed a series of significant cooperation agreements with partners including CATL, General Technology, Huachi Kinetic Energy, Huawei Digital Energy, Zhuhai Technology Group, Shuangdeng Group, Inovance, Wellpus, and Beijing Kerui, achieving a multi-scenario ecosystem layout centered on energy storage.
As a leading enterprise in the energy storage industry, HyperStrong is fully leveraging its role as a market leader to connect upstream and downstream segments of the energy storage industry and related fields, forming a vertical and horizontal three-dimensional ecosystem with industrial coordination and value orientation. The company has built a diverse, multi-dimensional industrial ecosystem matrix in the energy sector, continuously expanding the boundaries of cooperation and injecting sustained, strong momentum into the sustainable development of the energy industry.
04/
Yanyin Technology and Zhuanma Bio Unveil China's First CRISPR Gene Design Tool
Recently, China's first CRISPR gene design tool, jointly developed by Qiming Venture Partners portfolio company Yanyin Technology and Zhuanma Bio, was officially released — marking a milestone breakthrough for China in core gene editing technologies and contributing "Chinese wisdom" and "Chinese solutions" to the global life sciences field.
As a major upgrade to the molecular biology module of Yanyin's Intelligent Research Cloud Platform, the newly launched "CRISPR Tool" integrates Zhuanma Bio's deep expertise in gene editing enzymes with Yanyin Technology's powerful cloud-based scientific research collaboration capabilities, providing researchers with a one-stop CRISPR-Cas9 system gRNA (guide RNA) design and analysis solution that significantly improves the success rate and efficiency of gene editing experiments.
This CRISPR tool, powered by outstanding intelligent algorithms, will profoundly impact multiple critical fields. In medicine and healthcare, it will enable the development of new therapies to tackle major diseases such as genetic disorders and cancer. In agriculture and animal husbandry, it will accelerate crop and livestock improvement, significantly enhancing yield and quality while shortening breeding cycles. In biotechnology and research institutions, it will become a powerful engine driving fundamental research and the design of novel gene editing tools. In environmental protection, it will also provide unprecedented technical support for maintaining ecological balance and biodiversity.
05/
DeepWise Partners with Shenzhen International Science and Technology Information Center to Empower Shenzhen's Research Ecosystem
Recently, Science Navigator — a next-generation scientific research knowledge base and AI academic search platform developed by Qiming Venture Partners portfolio company DeepWise in collaboration with the AI for Science Institute, Beijing — following successful deployment at leading universities including Peking University and Wuhan University, has partnered with the Shenzhen International Science and Technology Information Center to explore a new cooperation paradigm focused on regional economic development and efficient industrial integration, empowering the upgrade of Shenzhen's research ecosystem with a fresh approach.
Science Navigator will deliver dual-track empowerment across academia and industry, with its core value lying in closing the loop between "knowledge creation" and "value creation." Real pain points and cutting-edge demands from industry are fed back to academia through the platform's data analysis, providing Shenzhen University Town's basic and applied research with more market-oriented research topics that make scientific work more grounded. Accelerated research outcomes are tested in industrial applications, with successful experiences or bottlenecks encountered becoming new drivers for deepening and advancing academic theory, forming a virtuous cycle of "practice — knowledge — further practice."
R&D Progress
01/
Ark Bio's Aizhida® NDA Accepted and Granted Priority Review
Recently, the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) formally accepted the New Drug Application (NDA) for Qiming Venture Partners portfolio company Ark Bio's Aizhida® (generic name: serdexmethylphenidate/dexmethylphenidate combination capsules) and granted it priority review status. The proposed indication is for the treatment of ADHD in patients aged 6 years and older.
Aizhida® (AK0901) is the world's first and currently only combination formulation containing immediate-release dexmethylphenidate (d-MPH) and the prodrug serdexmethylphenidate (SDX), representing a best-in-class innovative treatment for ADHD patients. It was approved in the United States in March 2021 and was the first methylphenidate drug approved by the FDA in nearly 20 years. Through its immediate-release + extended-release component design, it delivers comprehensive upgrades in clinical efficacy, safety, and tolerability.
02/
Abbisko Therapeutics Completes First Patient Dosing in Registrational Clinical Trial of Irpagratinib for Hepatocellular Carcinoma
Qiming Venture Partners portfolio company Abbisko Therapeutics (02256.HK) announced that its independently developed highly selective small-molecule FGFR4 inhibitor irpagratinib has completed first patient dosing in its registrational clinical trial for hepatocellular carcinoma.
Irpagratinib received Breakthrough Therapy designation from the CDE in May of this year. It is also the first drug to employ targeted molecular biomarkers for precision treatment of hepatocellular carcinoma.
03/
Zai Lab Releases New Preclinical Data on Self-Developed IL-13/IL-31R Bispecific Antibody ZL-1503 for Atopic Dermatitis
Recently, Qiming Venture Partners portfolio company Zai Lab (NASDAQ: ZLAB, 09688.HK) announced new preclinical study data for its innovative IL-13/IL-31R bispecific antibody ZL-1503, demonstrating its dual mechanism of simultaneously suppressing both the inflammatory and pruritic pathways in atopic dermatitis (AD). These findings were presented in the poster session at the 2025 European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress, highlighting ZL-1503's potential as an innovative treatment option for moderate-to-severe AD.
Key findings included: across all preclinical subjects, a single intravenous dose of ZL-1503 (10 mg/kg) completely suppressed IL-13-mediated pSTAT6 activation and IL-31-induced scratching behavior for at least 76 days. Among three subjects, two maintained IL-13-mediated pSTAT6 suppression for over 118 days, and one maintained IL-31-induced scratching suppression for over 133 days. Pharmacokinetic (PK) analysis of serum samples collected during the study showed that ZL-1503 has slow-clearance properties, with PK highly correlated to pharmacodynamic (PD) response, demonstrating a strong PK/PD relationship in blocking both IL-13 and IL-31 pathways in preclinical models. ZL-1503 remained well tolerated at weekly intravenous doses up to 150 mg/kg. In vitro studies further confirmed that binding to either target did not impair blockade of the other.
Corporate Development
Diluo Medical Holds Groundbreaking Ceremony for Color Soft Hydrophilic Contact Lens R&D and Production Base
Recently, Qiming Venture Partners portfolio company Diluo Medical held a groundbreaking ceremony in Gucun, Baoshan District, Shanghai for its color soft hydrophilic contact lens R&D and production base.
Upon completion, the base is projected to reach full production capacity of approximately 700 million lenses annually, generating 1.5 billion yuan in revenue and employing roughly 800 workers. At that point, Diluo Medical's total annual production capacity is expected to exceed 1.5 billion lenses, laying a solid foundation for a comprehensive product portfolio spanning color and clear soft contact lenses, functional lenses, as well as daily-wear RGP and overnight short-cycle orthokeratology (OK) lenses in the rigid lens category.
Product Launches
01/
Yao Medical Launches "Family Health Membership Plan"
Recently, Qiming Venture Partners portfolio company Yao Medical launched its "Family Health Membership Plan," a one-stop, whole-lifecycle family health management solution built on four pillars: prevention-first care, full-process management, personalized service, and multidisciplinary collaboration. The plan integrates premium medical resources from around the world.
Drawing on the mature system of the United Kingdom, member families gain access to a dedicated international family physician team led by experienced general practitioners and pediatricians. For specialist concerns, seamless referrals connect members to Yao Medical's 12 featured specialty centers or its network of public tertiary hospital experts. The plan provides an exclusive health service group with AI doctors available for rapid online consultation. For chronic disease management, the "Yao Health" digital platform helps members easily monitor data, receive medication reminders, and obtain personalized guidance. In emergencies, a dedicated 7×24 hotline connects members to professional teams immediately. Members bypass the difficulty of securing appointments, enjoying priority booking for Yao Medical's internal specialists and access to public tertiary hospital expert resources. Personalized health management also includes tailored physical examinations with in-depth report interpretation.
02/
Fukang Releases Smart Home Care Products and Forms Strategic Partnership with Coco Healthcare
At the 2025 Shanghai International Elderly Care and Rehabilitation Expo, Qiming Venture Partners portfolio company Fukang, a pioneer and leader in China's community-based home medical care, unveiled its latest smart home care products and achievements through a dedicated product launch.
Fukang officially introduced its "AI Butler + Care Butler" smart home care product suite — Private Dedicated Care and Patrol 360. These two service-oriented products address pain points and needs in elderly home care, pioneering a new dual-butler care model. By integrating intelligent technology into every aspect of actual care services, AI technology works alongside professional caregivers to doubly safeguard seniors living at home, building a closed-loop health ecosystem from prevention to wellness. The entire home care process becomes visualized and traceable, achieving one-stop smart home care spanning "medical treatment, nursing, rehabilitation, and eldercare."
Additionally, Fukang established a strategic partnership with Coco Healthcare, a leading enterprise in China's adult incontinence care sector. The two parties will deepen collaboration in smart home care to build a more comprehensive eldercare industry ecosystem, leveraging technology to connect the "service + technology + product" value chain and provide more reliable products and higher-quality services to more seniors.
Technology & Innovation
01/ Galaxy Universal Debuts at 2025 Beijing BAAI Conference, Unveils Core Achievements GroceryVLA and OpenWBT
Recently, He Wang, assistant professor at Peking University, founder and CTO of Qiming Venture Partners portfolio company Galaxy Universal, and BAAI scholar, was invited to speak at the opening roundtable of the 2025 Beijing BAAI Conference. Galaxy Universal's embodied large-model robot Galbot joined him on the main stage, demonstrating the company's latest technical achievements via global livestream and showcasing up close the industrial落地 capabilities of its embodied large-model-driven robotics.
The precise shelf-picking demonstrated by Galbot was powered by GroceryVLA, the end-to-end embodied large model newly developed by the Galaxy Universal team. In a 1:1 replica of a real supermarket scene built on-site, it achieved fully autonomous execution of complex shelf grasping and delivery workflows. What was demonstrated was not a temporarily choreographed demo, but a capability showcase for real commercial scenarios: from perception to action, from language instructions to precise manipulation — all completed autonomously by the model.
Additionally, Galaxy Universal jointly with the research team of assistant professor Li Yi at Tsinghua University officially released OpenWBT — the world's first fully open-source, multi-platform, cross-reality humanoid robot whole-body teleoperation system. This work innovatively achieves rapid deployment within hours. Users need only a VR headset and an ordinary computer to build and debug the system from scratch, quickly unlocking human-level operational freedom.
02/
Mofan Power Announces Successful Full-Load Ammonia Fuel Combustion Test of MGT8000 Pan-Hydrogen Gas Turbine
Recently, Qiming Venture Partners portfolio company Mofan Power announced consecutive major breakthroughs in MGT8000 pan-hydrogen gas turbine testing.
In February this year, the hydrogen storage and supply system was completed; in May, the ammonia storage and supply system was installed. From the first ignition of the pan-hydrogen fuel full-condition combustion test bench on March 18 to the successful completion of the MGT8000 full-load ammonia fuel combustion test on June 7, the team crossed from technical breakthrough to performance validation in just over 80 days, demonstrating with硬核 technical strength Mofan Power's accelerated innovation in clean energy.
03/ Pulnovo Medical PADN Series Achieves First Three Overseas Commercial Surgeries in UAE Hospital
Following European CE-MDR certification, Qiming Venture Partners portfolio company Pulnovo Medical recently achieved another major breakthrough — the PADN series completed its first three overseas commercial surgical applications at Al Qassimi Hospital in Sharjah, United Arab Emirates. This landmark achievement marks not only the first global deployment and translation of China's original pulmonary hypertension innovative therapy in a high-standard clinical environment worldwide, but also an important milestone for Pulnovo Medical in expanding international markets and serving global patients following its extensive clinical application in China.
Under the technical guidance of Professor Hang Zhang from Nanjing Medical University Affiliated Nanjing Hospital, Professor Arif Al Nooryani, a leading cardiologist at UAE's Al Qassimi Hospital, led his team in completing PADN procedures on three pulmonary hypertension patients. The surgeries proceeded smoothly, demonstrating the PADN system's excellent performance in operational simplicity, precision and safety, and clinical efficacy. Postoperative patient symptoms were significantly relieved and hemodynamic parameters markedly improved, laying a solid foundation for global application of the technology.
04/
Aohua Endoscopy Appears at Global Digestive Endoscopy Livestream Event
At a global digestive endoscopy livestream event, two experts from the Endoscopy Center of Zhongshan Hospital, Fudan University — Professor Pinghong Zhou and Professor Mingyan Cai — selected the AQ-300 4K ultra-high-definition endoscopy system from Qiming Venture Partners portfolio company Aohua Endoscopy (688212.SH) to perform two complex endoscopic surgeries, showcasing Chinese endoscopic technology capabilities to a global audience.
During both procedures, viewers worldwide witnessed through the livestream the ultra-high-definition surgical details rendered by the AQ-300. The system provided robust technical support for assessing lesion boundaries, delivering clear surgical visualization, and maintaining stable image transmission — clearly presenting every surgical step and operational nuance.
05/
M20 Genomics Appears at CHINAGUT 2025
China Gut Conference
At CHINAGUT 2025, Yongcheng Wang, Ph.D., a researcher at Zhejiang University and Chief Technology Officer of Qiming Venture Partners portfolio company M20 Genomics, delivered a presentation titled "Development and Application of High-Throughput Single-Cell and Single-Bacterium RNA Sequencing Technologies."
He noted that as gut microbiome research advances, there is growing need to develop single-cell-resolution tools for studying microbial function in order to reveal the heterogeneity and redundancy of microorganisms relevant to human health. However, due to the unique cellular structure of microbes, conventional single-cell transcriptomics techniques are not suitable for single-bacterium transcriptome studies of gut microbiota. To address this, M20 Genomics developed the world's first single-bacterium transcriptome technology for gut microbiota and launched the VITA Microbial Single-Cell Transcriptome Platform. The platform has been successfully applied to single-bacterium research of gut microbiota, providing powerful technical support for in-depth analysis of gut microbial functional mechanisms.
Beyond the academic presentation, M20 Genomics also exhibited the VITA platform at the conference. With its distinctive technical principles, efficient detection capabilities, and broad application prospects, the platform became a major highlight of the event. The VITA platform provides multi-dimensional detection data ranging from microbes to host organisms and from mRNA to non-coding RNA, offering efficient detection methods for studying how microorganisms respond to environmental stress, maintain biological functional integrity, and employ survival strategies and molecular mechanisms when infecting hosts.
06/
Jialiang Medical Debuts Core Products at
The Health Industry Series — ASEAN
Recently, Qiming Venture Partners portfolio company Jialiang Medical debuted its core products at The Health Industry Series — ASEAN. Under the theme "Innovation-Driven Precision Medicine," the company highlighted its next-generation LaserRO™ MRI-guided laser ablation minimally invasive surgery system.
Jialiang Medical has built advanced technology platforms in brain-computer modulation, medical lasers, and brain-computer chips, providing innovative device solutions for multiple neurological disorders. Its developed products include an MRI-guided laser ablation surgery system (LITT) for brain minimally invasive procedures, an implantable closed-loop self-responsive neurostimulation system for treating epilepsy and Parkinson's disease, and intracranial deep-brain electrodes, with some products already entering formal clinical trials.
07/
Xinze Source Presents Full-Chain Minimally Invasive
Medical Solutions at 2025 Medical Endoscopy Technology Development Conference
Recently, Qiming Venture Partners portfolio company Xinze Source presented its full-chain minimally invasive medical solutions at the 2025 Medical Endoscopy Technology Development Conference, exploring new directions in endoscopy technology development through its precision manufacturing capabilities and cutting-edge product portfolio. From regulatory compliance to innovative R&D, from core components to finished devices, Xinze Source comprehensively showcased frontier achievements in the endoscopy field to support high-quality industry development.
During the conference, Xinze Source focused on the full chain of endoscopy "core components — complete systems — clinical applications," highlighting four major product systems: precision component series, endoscopic consumables and components, minimally invasive surgical instruments and components, and endoscopy system solutions. Through physical displays, technical explanations, and scenario-based experiences, the company presented solutions covering the entire endoscopy industry chain.
Corporate Honors
Four Qiming Venture Partners Portfolio Companies Win 2025 Science and Innovation Golden Bull Awards
The winners of the 2025 Science and Innovation Golden Bull Awards were recently announced. The "Golden Bull Awards" are among the most influential honors in China's capital markets. The Science and Innovation Golden Bull Awards aim to fully leverage their role in promoting the integration of technological and industrial innovation and serving the real economy, helping China's emerging high-tech industries take critical steps forward. This year's awards centered on the theme of technological innovation, focusing on eight strategic emerging industries including next-generation information technology, artificial intelligence, and biomedicine, showcasing outstanding listed and unlisted companies in these fields while recognizing the patient capital that diligently supports the emergence of new high-tech enterprises.
Qiming Venture Partners portfolio company SinoCellTech (688520.SH) won the Golden Bull Listed Company Science and Innovation Award, while Biren Technology, Sinotau Pharmaceutical, and Shenogen Pharma won the Golden Bull Science and Innovation Enterprise Award.
Previous Coverage
Qiming Weekly | Qiming Venture Partners Portfolio Company Funding and Updates Vol. 20, 2025
Qiming Stars | Global Smart Imaging Leader Insta360 Successfully Lists on STAR Market
Qiming Venture Partners was founded in 2006. The firm currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, Qiming Venture Partners has focused on investing in early and growth-stage outstanding enterprises in the Technology and Consumer (T&C) and Healthcare sectors.
To date, Qiming Venture Partners has invested in more than 580 high-growth innovative companies. Over 210 of these have gone public on exchanges including the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, the Shanghai Stock Exchange, and the Shenzhen Stock Exchange, or have exited through mergers and acquisitions. More than 80 have become recognized unicorns or super-unicorns in their industries.
Among Qiming Venture Partners' portfolio companies, many have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ: BILI, 09626.HK), Zhihu (NYSE: ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ: WRD), Insta360 (688775.SH), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ: ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ: SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), SinoCellTech (688520.SH), Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, and Biren Technology.